Anaphylaxis in dogs and cats.

Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)

Volumn 23, Issue 4, 2013, Pages 377-394

  Shmuel, Daniella L ^a   Cortes, Yonaira ^b  

^a Oradell Animal Hospital   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHYLAXIS; ANIMAL; CAT; CAT DISEASES; DOG; DOG DISEASES; PATHOPHYSIOLOGY; VETERINARY;

ANAPHYLAXIS; ANIMALS; CAT DISEASES; CATS; DOG DISEASES; DOGS;

EID: 84896564277     PISSN: None     EISSN: 14764431     Source Type: Journal    
DOI: None     Document Type: Review

References (143)

1. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium. J Allergy Clin Immunol 2006; 117(2):391-397.
2. Simons FE, Ardusso LR, Bilo MB, et al.WorldAllergyOrganization anaphylaxis guidelines: summary. J Allergy Clin Immunol 2011; 127(3):587-593.e1-e22.
3. Lieberman P. Definition and criteria for the diagnoses of anaphylaxis, In: Castells MC. ed. Anaphylaxis and Hypersensitivity Reactions. New York: Humana Press; 2011, pp. 1-12.
4. Johnson RF, Peebles RS. Anaphylactic shock: pathophysiology, recognition, and treatment. Semin Respir Crit Care Med 2004; 25(6):695-703.
5. Chan EA. Anaphylaxis and anaesthesia. Vet Anaesth Analg 2010; 37(4):306-310.
6. Baer GM, Goodrich WO, Dean DJ. Death from anaphylactic shock in a dog vaccinated with anti-rabies vaccine of chicken embryo origin. J Am Vet Med Assoc 1962; 141:1048.
7. Mason TA. Anaphylactic response to thiopentone in a dog. Vet Rec 1976; 98(7):136.
8. Ward GS, Guiry CC, Alexander LL. Tetracycline-induced anaphylactic shock in a dog. J Am Vet Med Assoc 1982; 180(7):770-771.
9. Waechter RA. Unusual reaction to acepromazine maleate in the dog. J Am Vet Med Assoc 1982; 180(1):73-74.
10. Davis LE. Hypersensitivity reactions induced by antimicrobial drugs. J Am Vet Med Assoc 1984; 185(10):1131-1136.
11. Raptopoulos D, Papazoglou L, Galatos A. Suspected adverse reaction to xylazine-ketamine anesthesia in a cat. Feline Pract 1993; 21:27-29.
12. Kushner LI, Trim CM. Suspected thiopental-induced anaphylaxis in a dog. J Am An Hosp Assoc 1994; 30(5):451-456.
13. Meyer EK. Rare, idiosyncratic reaction to acepromazine in dogs. J Am Vet Med Assoc 1997; 210(8):1114-1115.
14. Pollard RE, Pascoe PJ. Severe reaction to intravenous administration of an ionic iodinated contrast agent in two anesthetized dogs. J Am Vet Med Assoc 2008; 233(2):274-278.
15. Schaer M, Ginn PE, Hanel RM. A case of fatal anaphylaxis in a dog associated with a dexamethasone suppression test. J Vet Emerg Crit Care 2005; 15(3):213-216.
16. Girard NM, Leece EA. Suspected anaphylactoid reaction following intravenous administration of a gadolinium-based contrast agent in three dogs undergoing magnetic resonance imaging. Vet Anaesth Analg 2010; 37(4):352-356.
17. Burren VS, Mason KV. Suspected anaphylaxis to thiopentone in a dog. Aust Vet J 1986; 63(11):384-385.
18. Plunkett SJ. Anaphylaxis to ophthalmic medication in a cat. J Vet Emerg Crit Care 2000; 10(3):169-171.
19. Walker T, Tidwell AS, Rozanski EA, et al. Imaging diagnosis: acute lung injury following massive bee envenomation in a dog. Vet Radiol Ultrasound 2005; 46(4):300-303.
20. Cowell AK, Cowell RL, Tyler RD, et al. Severe systemic reactions to Hymenoptera stings in three dogs. J Am Vet Med Assoc 1991; 198(6):1014-1016.
21. Acute reactions in dogs treated with doxorubicin: increased frequency with the use of a generic formulation. J Vet Intern Med 1998; 12(3):171-172.
22. Carter JE, Chanoit G, Kata C. Anaphylactoid reaction in a heartworm-infected dog undergoing lung lobectomy. J Am Vet Med Assoc 2011; 238(10):1301-1304.
23. Antin IP. Fatal anaphylactic reaction of dog to bee sting. J Am Vet Med Assoc 1963; 142:775.
24. Hume-Smith KM, Groth AD, Rishniw M, et al. Anaphylactic events observed within 4 h of ocular application of an antibioticcontaining ophthalmic preparation: 61 cats (1993-2010). J Feline Med Surg 2011; 13(10):744-751.
25. Davidson MG, Baty KT. Anaphylaxis associated with intravenous sodium fluorescein administration in a cat. Prog Vet Comp Ophthalmol 1991; 1:127-128.
26. Simons FE. Anaphylaxis. JAllergy Clin Immunol 2010; 125(2 Suppl 2):S161-S181.
27. Sampson HA, Munoz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 2005; 115(3):584-591.
28. Lucke WC, Thomas H. Anaphylaxis: pathophysiology, clinical presentations and treatment. J Emerg Med 1983; 1(1):83-95.
29. Nurmatov U, Worth A, Sheikh A. Anaphylaxismanagement plans for the acute and long-termmanagement of anaphylaxis: a systematic review. J Allergy Clin Immunol 2008; 122(2):353-361.
30. Lieberman P, Camargo CA Jr., Bohlke K, et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol 2006; 97(5):596-602.
31. Simons FE. Anaphylaxis. J Allergy Clin Immunol 2008; 121 (Suppl 2):S402-S407.
32. Metcalfe DD, Peavy RD, Gilfillan AM. Mechanisms of mast cell signaling in anaphylaxis. J Allergy Clin Immunol 2009; 124(4):639-646.
33. Khan BQ, Kemp SF. Pathophysiology of anaphylaxis. Curr Opin Allergy Clin Immunol 2011; 11(4):319-325.
34. Finkelman FD. Anaphylaxis: lessons from mousemodels. J Allergy Clin Immunol 2007; 120(3):506-515.
35. Kalesnikoff J, Galli SJ. Anaphylaxis: mechanisms of mast cell activation. Chem Immunol Allergy 2010; 95:45-66.
36. Nauta A, Knippels L, Garssen J, et al. Animal models of anaphylaxis. Curr Opin Allergy Clin Immunol 2007; 7(4):355-359.
37. Long A. The nuts and bolts of peanut allergy. N Engl J Med 2002; 346(17):1320-1322.
38. Lee JK, Vadas P. Anaphylaxis: mechanisms andmanagement. Clin Exp Allergy 2011; 41(7):923-938.
39. Kemp SF, Lockey RF. Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol 2002; 110 (3):341-348.
40. Peavy RD, Metcalfe DD. Understanding the mechanisms of anaphylaxis. Curr Opin Allergy Clin Immunol 2008; 8(4): 310-315.
41. Moore GE, HogenEsch H. Adverse vaccinal events in dogs and cats. Vet Clin N Am Small Anim Pract 2010; 40(3): 393-407.
42. Shibamoto T, Liu W, Cui S, et al. PAF, rather than histamine, participates in mouse anaphylactic hypotension. Pharmacology 2008; 82(8):114-120.
43. Strait RT, Morris SC, Finkelman FD. IgG-blocking antibodies inhibit IgE mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking. J Clin Invest 2006; 116(3):833-841.
44. Jänsson F, Mancardi D, Kita Y, et al. Mouse and human neutrophils induce anaphylaxis. J Clin Invest 2011; 121(4):1484-1496.
45. Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med 2001; 344(1):30-37.
46. Lieberman P. Anaphylaxis and anaphylactoid reactions. In: Adkinson NF Jr., Yunginger JW, Busse WW, et al. eds. Middleton’s Allergy: Principles and Practice, 6th ed. St Louis, MO: Mosby-Year Book; 2003, pp.1497-1522.
47. Simons FE, Frew AJ, Ansotegui IJ, et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol 2007; 120(1 Suppl):S2-24.
48. Stone SF, Cotterell C, IsbisterGK. Elevated serumcytokines during human anaphylaxis: identification of potential mediators of acute allergic reactions. J Allergy Clin Immunol 2009; 124 (4):786-792.
49. Tran PT, Muelleman RL. Allergy, hypersensitivity and anaphylaxis. In: Marx JA, Hockberger RS, Walls RM. eds. Rosen’s Emergency Medicine, Concepts and Clinical Practice. Philadelphia, PA:Mosby Elsevier; 2006, pp. 1818-1838.
50. Pushparaj PN, Tay HK, H’ng SC, et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA 2009; 106(24):9773-9778.
51. Simons FE, Anaphylaxis: recent advances in assessment and treatment. J Allergy Clin Immunol 2009; 124(4):625-636.
52. Mathias CB, Hobson SA, Garcia-Lloret M, et al. IgE-mediated systemic anaphylaxis and impaired tolerance to food antigens in mice with enhanced IL-4 receptor signaling. J Allergy Clin Immunol 2011; 127(3):795-805.
53. Smith PL, Kagey-Sobotka A, Bleecker ER, et al. Physiologic manifestations of human anaphylaxis. J Clin Invest 1980; 66(5):1072-1980.
54. Richard V, Hurel-Merle S, Scalbert E, et al. Functional evidence for a role of vascular chymase in the production of angiotensin II in isolated human arteries. Circulation 2001; 104(7):750-752.
55. Dykewicz MS. Anaphylaxis and inflammation. Clin Allergy Immunol 2002; 16:401-409.
56. Lieberman P, Nicklas, MD, Oppenheimer J. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010; 126(3):477-480.
57. Dowling PM. Anaphylaxis. In: Silverstein DC, Hopper K. eds. Small Animal Critical Care Medicine. St Louis, MO: Saunders Elsevier; 2009, pp. 727-730.
58. Schwartz LB, Riedel C, Caulfield JP, et al. Cell association of complexes of chymase, heparin proteoglycan, and protein after degranulation by rat mast cells. J Immunol 1981; 126(6):2071-2078.
59. Peters LJ, Kovacic JP. Histamine: metabolism, physiology, and pathophysiology with applications in veterinary medicine. J Vet Emerg Crit Care 2009; 19(4):311-328.
60. Watt AP, Ennis M. Characterization of histamine release by mast cells, basophils, monocytes. In: Falus A. ed. Histamine: Biology and Medical Aspects. Budapest, Hungary: SpringMed Publishing Ltd; 2004, pp. 99-111.
61. Herjavecz I, Hirschberg A. Histamine and allergy. In: Falus A. ed. Histamine: Biology and Medical Aspects. Budapest, Hungary: SpringMed Publishing Ltd; 2004, pp. 140-157.
62. Chrusch C, Sharma S, Unruh H, et al.Histamine H3 receptor blockade improves cardiac function in canine anaphylaxis. Am J Respir Crit Care Med 1999; 160(4):1142-1149.
63. Felix SB, Baumann G, Helmus S, et al. The role of histamine in cardiac anaphylaxis; characterization of histaminergic H1 and H2 effects. Basic Res Cardiol 1998; 83(5):531-539.
64. Tucker A, Weir EK, Reeves TJ, et al. HistamineH1 and H2 receptors in pulmonary and systemic vasculature of the dog. Am J Physiol 1975; 229(4):1008-1013.
65. McNeill JH. Histamine and the heart. Can J Physiol Pharmacol 1984; 62(6):720-726.
66. Dunford PJ, Williams KN, Desai PJ, et al. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol 2007; 119(1):176-183.
67. Smyth EM, Burke A, FitzGerald G. Lipid derived autacoids: eicosanoids and platelet activating factor. In: Brunton LL, Lazo JS, Parker KL. eds. Goodman and Gilman’s: The Pharmacological Basis of Therapeutics, 11th edn. New York: McGraw-Hill; 2006, pp. 653-670.
68. Bochner BS, Lichtenstein LM. Anaphylaxis. N Eng J Med 1991; 324(25):1785-1790.
69. Greenberger PA, Rotskoff BD, Lifschultz B. Fatal anaphylaxis: postmortem findings and associated comorbid diseases. Ann Allergy Asthma Immunol 2007; 98(3):252-257.
70. Cohen RD. Systemic anaphylaxis. In: Bonagura JD, Kirk RW. eds. Kirk’s Current Veterinary Therapy XII Small Animal Practice. Philadelphia, PA:WB Saunders Co; 1995, pp. 150-152.
71. Waddell L. Systemic anaphylaxis. In: Ettinger SJ, Feldman EC. eds. Textbook of Veterinary Internal Medicine, 6th edn. Philadelphia, PA:WB Saunders Co; 2005, pp. 458-460.
72. Boothe DM. Adverse reactions to therapeutic drugs in the CCU patient. In:WingfieldWE, RaffeMR. eds. TheVeterinary ICUBook. Jackson Hole, WY: Teton New Media; 2002, pp. 1049-1056.
73. Quantz JE, Miles MS, Reed AL, et al. Elevation of alanine transaminase and gallbladder wall abnormalities as biomarkers of anaphylaxis in canine hypersensitivity patients. J Vet Emerg Crit Care 2009; 19(6):536-544.
74. Litster A, Atwell R. Physiological and haematological findings and clinical observations in a model of acute systemic anaphylaxis in Dirofilaria immitis sensitized cats. Aust Vet J 2006; 84(5):151-157.
75. Mc Cusker HB, Aitken ID. Anaphylaxis in the cat. J Pathol Bacteriol 1966; 91(1):282-285.
76. Aitken ID, McCusker HB. Feline anaphylaxis: some observations. Vet Rec 1969; 84(3):58-61.
77. Dean HR, Webb RA. The morbid anatomy and histology of anaphylaxis in the dog. J Pathol Bacteriol 1924; 27(1): 57-64.
78. Lautt WW, Legare DJ. Effect of histamine, norepinephrine, and nerves on vascular pressures in dog liver. AmJ Physiol 1987; 252(4, Part 1):G472-G478.
79. Richardson PD, Withrington PG. Responses of the simultaneously perfused hepatic arterial and portal venous vascular beds of the dog to histamine and 5-hydroxytryptamine. Br J Pharmacol 1978; 64(4):581-588.
80. Bain PJ. Liver. In: Latimer KS, Mahaffey EA, Prasse KW. eds. Duncan & Prasse’s Veterinary Laboratory Medicine. 4th ed. Ames, IA: Blackwell Publishing; 2003, pp. 193-214.
81. Kapin MA, Ferguson JL. Hemodynamic and regional circulatory alterations in dog during anaphylactic challenge. Am. J. Physiol. 1985; 249 (Heart Circ. Physiol. 18): H430-H437.
82. Keller WC, Bataller N. Adverse drug reactions. In: Bonagura JD. ed. Kirk’s Current Veterinary Therapy XIII—Small Animal Practice. Philadelphia, PA:WB Saunders; 2000, pp. 239-242.
83. Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004; 114(2):371-376.
84. Brown SG. Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis. Curr Opin Allergy Clin Immunol 2005; 5(4):359-364.
85. Fisher MM. Clinical observations on the pathophysiology and treatment of anaphylactic cardiovascular collapse. Anaesth Intensive Care 1986; 14(1):17-21.
86. Mair AR, Wooley J, Martinez M. Cardiovascular effects of intravenous gadolinium administration to anaesthetised dogs undergoing magnetic resonance imaging. Vet Anaesth Analg 2010; 37(4):337-341.
87. Ben-Shoshan M, Clarke AE. Anaphylaxis: past, present and future. Allergy 2011; 66(1):1-14.
88. Henmi H. Studies on the hepatic circulation in anaphylactic shock with special reference to the plasma concentration of catecholamines. Jpn Circ J 1965; 29(5):461-469.
89. Chamberlain KW, Baker E. A brief discussion of allergic diseases of other organs and systems. Vet Clin NorthAm1974; 4(1):175-186.
90. Kitoh K, Kitagawa H, Sasaki Y. Pathologic findings in dogs with shock induced by intravenous administration of heartworm extract. Am J Vet Res 1998; 59(11):1417-1422.
91. Moore GE, DeSantis-Kerr AC, Guptill LF, et al. Adverse events after vaccine administration in cats: 2, 560 cases (2002-2005). J Am Vet Med Assoc 2007; 231(1):94-100.
92. Moore GE, Guptill LF, Ward MP, et al. Adverse events diagnosed within three days of vaccine administration in dogs. J AmVet Med Assoc 2005; 227(7):1102-1108.
93. Ohmori K, Masuda K, Maeda S, et al. IgE reactivity to vaccine components in dogs that developed immediate-type allergic reactions after vaccination. Vet Immunol Immunopathol 2005; 104(3-4):249-256.
94. Kemp SF, Lockey RF, Simons FE. Epinephrine: the drug of choice for anaphylaxis: a statement of the World Allergy Organization. Allergy 2008; 63(8):1061-1070.
95. Lieberman P. Biphasic anaphylactic reactions. AnnAllergyAsthma Immunol 2005; 95(3):217-226.
96. Joint Task Force on Practice Parameters. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol 2005; 115(3 Suppl 2):S483-S523.
97. Berdoulay P, Schaer M, Starr J. Serum sickness in a dog associated with antivenin therapy for snake bite caused by Crotalus adamanteus. J Vet Emerg Crit Care 2005; 15(3):206-212.
98. Slauson DO, Cooper BJ. Mechanisms of Disease: A Textbook of ComparativeGeneral Pathology, 2nd edn.Baltimore, MD:Williams and Wilkins; 1990, pp.330-376.
99. Gitlin JD. Allergy and immunology. In: Rudolph CD. ed. Rudolph’s Pediatrics, 21st ed.NewYork, NY:McGraw-Hill; 2002, pp. 787-824.
100. Riott I. Hypersensitivity. In: Delves PJ. ed. Essential Immunology, 9th ed. Oxford: Blackwell Science Ltd; 1997, pp. 328-352.
101. Janeway CA. Type III hypersensitivity. In: Travers P, Walport M, Shlomchik MJ. eds. Immunobiology. New York: Garland Publishing; 2001, pp. 517-555.
102. Francis AH, Martin LG, Haldorson GJ, et al. Adverse reactions suggestive of type III hypersensitivity in six healthy dogs given human albumin. J Am Vet Med Assoc 2007; 230(6):873-879.
103. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000; 30(8):1144-1150.
104. Soar J, Pumphrey RS, Cant A, et al. Emergency treatment of anaphylactic reactions: guidelines for healthcare providers. Resuscitation 2008; 77(2):157-169.
105. Cowell AK, Cowell RL. Management of bee and other hymenoptera stings. In: Bonagura JD, Kirk RW, eds. Kirk’s Current Veterinary Therapy XII Small Animal Practice. Philadelphia, PA: WB Saunders; 1995, pp. 226-228.
106. Fitzgerald KT, Flood AA. Hymenoptera stings. Clin Tech Small Anim Pract 2006; 21(4):194-204.
107. Campbell TW. Bites and stings. In: Wingfield WE, Raffe MR, eds. The Veterinary ICU Book. Jackson Hole, WY: Teton New Media; 2002, pp. 1017-1019.
108. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin N Am 2006; 26(3): 451-463.
109. Fernandez AL, Lee JA, Rahilly L, et al. The use of intravenous lipid emulsion as an antidote in veterinary toxicology. J Vet Emerg Crit Care 2011; 21 (4):309-320.
110. Driscoll DF. Lipid injectable emulsions: pharmacopeial and safety issues. Pharm Res 2006; 23(9):1959-1969.
111. Turner-Lawrence DE, Kerns W II. Intravenous fat emulsion: a potential novel antidote. J Med Toxicol 2008; 4(2):109-114.
112. Vadas P, Gold M, Perelman B, et al. Platelet-activating factor, PAF acetylhydrolase and severe anaphylaxis. N Engl J Med 2008; 358(1):28-35.
113. Yong PF, Birns J, IbrahimMA. Anaphylactic shock: the great mimic. S Med J 2007; 100(3):295-297.
114. Lieberman P. Use of epinephrine in the treatment of anaphylaxis. Curr Opin Allergy Clin Immunol 2003; 3(4):313-318.
115. Simons KJ, Simons FE. Epinephrine and its use in anaphylaxis: current issues. Curr Opin Allergy Clin Immunol 2010; 10(4):354-361.
116. Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Brunton LL, Lazo JS, Parker KL. eds. Goodman and Gilman’s: The Pharmacological Basis of Therapeutics, 11th ed. New York: McGraw-Hill; 2006, pp. 237-247.
117. Gu X, Simons FE, Simons KJ. Epinephrine absorption after different routes of administration in an animal model. Biopharm Drug Dispos 1999; 20(8):401-405.
118. Triggiani M, Patella V, Staiano RI, et al. Allergy and the cardiovascular system. Clin Exp Immunol 2008; 153(Suppl 1):7-11.
119. Mueller UR. Cardiovascular disease and anaphylaxis. Curr Opin Allergy Clin Immunol 2007; 7(4):337-341.
120. Mink SN, Bands C, Becker A, et al. Effect of bolus epinephrine on systemic hemodynamics in canine anaphylactic shock. Cardiovasc Res 1998; 40(3):546-556.
121. Mink SN, Simons FE, Simons KJ, et al. Constant infusion of epinephrine, but not bolus treatment, improves haemodynamic recovery in anaphylactic shock in dogs. Clin Exp Allergy 2004; 34(11):1776-1783.
122. Bautista E, Simons FE, Simons KJ, et al. Epinephrine fails to hasten hemodynamic recovery in fully developed canine anaphylactic shock. Int Arch Allergy Immunol 2002; 128(2):151-164.
123. Simons FE, for theWorld Allergy Organization. Epinephrine autoinjectors: first-aid treatment still out of reach formany at risk of anaphylaxis in the community. Ann Allergy Asthma Immunol 2009; 102(5):403-409.
124. Stecher D, Bulloch B, Sales J, et al. Epinephrine auto-injectors: is needle length adequate for delivery of epinephrine intramuscularly? Pediatrics 2009; 124(1):65-70.
125. Sheikh A, Ten Broek V, Brown SG, et al. H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. Allergy 2007; 62(8):830-837.
126. Silverman HJ, TaylorWR, Smith PL, et al. Effects of antihistamines on the cardiopulmonary changes due to canine anaphylaxis. JAppl Physiol 1988; 64(1):210-217.
127. Felix SB, Baumann G, Niemczyk M, et al. Effects of histamine H1-and H2-receptor antagonists on cardiovascular function during systemic anaphylaxis in guinea pigs. Agents Actions 1991; 32(3-4):245-252.
128. Bellou A, Lambert H, Gillois P, et al. Constitutive nitric oxide synthase inhibition combined with histamine and serotonin receptor blockade improves the initial ovalbumin-induced arterial hypotension but decreases the survival time in brown Norway rats anaphylactic shock. Shock 2003; 19(1):71-78.
129. Simons FE. Advances in H1-antihistamines. N Engl J Med 2004; 351(21):2203-2217.
130. Simons FE. Pharmacologic treatment of anaphylaxis: can the evidence base be strengthened? Curr Opin Allergy Clin Immunol 2010; 10(4):384-393.
131. Lin RY, Curry A, Pesola GR, et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med 2000; 36(5):462-468.
132. Runge JW, Martinez JC, Caraveti EM, et al. Histamine antagonists in the treatment of acute allergic reactions. Ann Emerg Med 1992; 21(3):237-242.
133. Plumb DC. Plumb’s Veterinary Drug Handbook, 6th ed. Ames, IA: Blackwell Publishing; 2008.
134. Choo KJ, Simons FE, Sheikh A. Glucocorticoids for the treatment of anaphylaxis: Cochrane systematic review. Allergy 2010; 65(10):1205-1211.
135. Schleimer RP. Pharmacology of glucocorticoids in allergic disease. In: Adkinson NF Jr., Yunginger JW, Busse WW, et al. eds. Middleton’s Allergy Principles and Practice, 7th ed. St Louis, MO: Mosby Inc; 2008, pp. 1549-1574.
136. Mathews KA. Indications and guidelines for ‘‘fluid’’ management in various situations. In: Proceedings of the Western Veterinary Conference. Las Vegas, NV; 2004, pp. 654-656.
137. Scroggin RD Jr., Quandt J. The use of vasopressin for treating vasodilatory shock and cardiopulmonary arrest. J Vet Emerg Crit Care 2009; 19(2):145-157.
138. Kill C, Wranze E, Wulf H. Successful treatment of severe anaphylactic shock with vasopressin. Two case reports. Int Arch Allergy Immunol 2004; 134(3):260-261.
139. Tsuda A, Tanaka KA, Huraux C, et al. The in vitro reversal of histamine-induced vasodilation in the human internal mammary artery. Anesth Analg 2001; 93(6):1453-1459.
140. Silverstein DC, Waddell LS, Drobatz KJ, et al. Vasopressin therapy in dogs with dopamine resistant hypotension and vasodilatory shock. J Vet Emerg Crit Care 2007; 17(4):399-408.
141. Thomas M, Crawford I. Best evidence topic report. Glucagon infusion in refractory anaphylactic shock in patients on beta-blockers. Emerg Med J 2005; 22(4):272-273.
142. Jackson HA, Jackson MW, Coblentz L, et al. Evaluation of the clinical and allergen specific serum immunoglobulin E responses to oral challenge with cornstarch, corn, soy and a soy hydrolysate diet in dogs with spontaneous food allergy. Vet Dermatol 2003; 14(4):181-187.
143. Hepner DL, Castells MC. Anaphylaxis during the perioperative period. Anesth Analg 2003; 97(5):1381-1395.